Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth

Maria Giovanna Scioli, Simona Artuso, Carmen D’Angelo, Manuela Porru, Federico D’Amico, Alessandra Bielli, Pietro Gentile, Valerio Cervelli, Carlo Leonetti, Augusto Orlandi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Breast cancer represents the main malignancy in women and autologous fat grafting is a diffuse procedure in the management of post-surgical breast defects causing patients’ psychosocial problems, with high costs for the public health. Recently, beneficial effects of fat grafting during post-surgical breast reconstruction have been amplified from the enrichment with human adipose-derived stem cells (ASCs) present in the stromal vascular fraction (SVF) of adult adipose tissue isolated during intraoperatory procedures. The major concern about the ASC enrichment during post-surgery breast reconstruction depends on their potential ability to release growth factors and hormones that can promote proliferation of residual or quiescent cancer cells, with the risk of de novo cancer development or recurrence. The recent description that adult stem cells primed in vitro may be vehicle for anticancer drug delivery offers a new vision concerning the role of ASCs in breast reconstruction after cancer surgery. Paclitaxel (PTX) is a chemotherapeutic agent acting as a microtu-bule-stabilizing drug inhibiting cancer cell mitotic activity. We optimized PTX loading and release in cultured ASCs and then analyzed the effects of PTX-loaded ASCs and their conditioned medium on CG5 breast cancer survival, proliferation and apoptosis in vitro, and inCG5 xenograft in vivo. We documented that ASCs can uptake and release PTX in vitro, with slight cytotoxic effects. Interestingly, PTX-loaded ASCs in co-culture, as well as conditioned medium alone, inhibited CG5 cell proliferation and survival in vitro and xenograft tumor growth in vivo. The antitumor effect of PTX-loaded ASCs may offer a new perspective concerning the use of ASCs during breast reconstruction becoming an additional local preventive chemotherapeutic agent against tumor recurrence. However, further experiments in vitro and in vivo are needed to collect more evidence confirming the efficacy and safety in cancer patients.

Original languageEnglish
Pages (from-to)e0203426
JournalPLoS One
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

paclitaxel
Paclitaxel
Stem cells
breast neoplasms
stem cells
Stem Cells
Breast Neoplasms
Mammaplasty
Growth
breasts
Neoplasms
neoplasms
Conditioned Culture Medium
Heterografts
Surgery
Tumors
surgery
Fats
Cells
Recurrence

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Scioli, M. G., Artuso, S., D’Angelo, C., Porru, M., D’Amico, F., Bielli, A., ... Orlandi, A. (2018). Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. PLoS One, 13(9), e0203426. https://doi.org/10.1371/journal.pone.0203426

Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. / Scioli, Maria Giovanna; Artuso, Simona; D’Angelo, Carmen; Porru, Manuela; D’Amico, Federico; Bielli, Alessandra; Gentile, Pietro; Cervelli, Valerio; Leonetti, Carlo; Orlandi, Augusto.

In: PLoS One, Vol. 13, No. 9, 01.09.2018, p. e0203426.

Research output: Contribution to journalArticle

Scioli, MG, Artuso, S, D’Angelo, C, Porru, M, D’Amico, F, Bielli, A, Gentile, P, Cervelli, V, Leonetti, C & Orlandi, A 2018, 'Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth', PLoS One, vol. 13, no. 9, pp. e0203426. https://doi.org/10.1371/journal.pone.0203426
Scioli, Maria Giovanna ; Artuso, Simona ; D’Angelo, Carmen ; Porru, Manuela ; D’Amico, Federico ; Bielli, Alessandra ; Gentile, Pietro ; Cervelli, Valerio ; Leonetti, Carlo ; Orlandi, Augusto. / Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. In: PLoS One. 2018 ; Vol. 13, No. 9. pp. e0203426.
@article{14571cd358354bae885fa783ff5b977c,
title = "Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth",
abstract = "Breast cancer represents the main malignancy in women and autologous fat grafting is a diffuse procedure in the management of post-surgical breast defects causing patients’ psychosocial problems, with high costs for the public health. Recently, beneficial effects of fat grafting during post-surgical breast reconstruction have been amplified from the enrichment with human adipose-derived stem cells (ASCs) present in the stromal vascular fraction (SVF) of adult adipose tissue isolated during intraoperatory procedures. The major concern about the ASC enrichment during post-surgery breast reconstruction depends on their potential ability to release growth factors and hormones that can promote proliferation of residual or quiescent cancer cells, with the risk of de novo cancer development or recurrence. The recent description that adult stem cells primed in vitro may be vehicle for anticancer drug delivery offers a new vision concerning the role of ASCs in breast reconstruction after cancer surgery. Paclitaxel (PTX) is a chemotherapeutic agent acting as a microtu-bule-stabilizing drug inhibiting cancer cell mitotic activity. We optimized PTX loading and release in cultured ASCs and then analyzed the effects of PTX-loaded ASCs and their conditioned medium on CG5 breast cancer survival, proliferation and apoptosis in vitro, and inCG5 xenograft in vivo. We documented that ASCs can uptake and release PTX in vitro, with slight cytotoxic effects. Interestingly, PTX-loaded ASCs in co-culture, as well as conditioned medium alone, inhibited CG5 cell proliferation and survival in vitro and xenograft tumor growth in vivo. The antitumor effect of PTX-loaded ASCs may offer a new perspective concerning the use of ASCs during breast reconstruction becoming an additional local preventive chemotherapeutic agent against tumor recurrence. However, further experiments in vitro and in vivo are needed to collect more evidence confirming the efficacy and safety in cancer patients.",
author = "Scioli, {Maria Giovanna} and Simona Artuso and Carmen D’Angelo and Manuela Porru and Federico D’Amico and Alessandra Bielli and Pietro Gentile and Valerio Cervelli and Carlo Leonetti and Augusto Orlandi",
year = "2018",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0203426",
language = "English",
volume = "13",
pages = "e0203426",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth

AU - Scioli, Maria Giovanna

AU - Artuso, Simona

AU - D’Angelo, Carmen

AU - Porru, Manuela

AU - D’Amico, Federico

AU - Bielli, Alessandra

AU - Gentile, Pietro

AU - Cervelli, Valerio

AU - Leonetti, Carlo

AU - Orlandi, Augusto

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Breast cancer represents the main malignancy in women and autologous fat grafting is a diffuse procedure in the management of post-surgical breast defects causing patients’ psychosocial problems, with high costs for the public health. Recently, beneficial effects of fat grafting during post-surgical breast reconstruction have been amplified from the enrichment with human adipose-derived stem cells (ASCs) present in the stromal vascular fraction (SVF) of adult adipose tissue isolated during intraoperatory procedures. The major concern about the ASC enrichment during post-surgery breast reconstruction depends on their potential ability to release growth factors and hormones that can promote proliferation of residual or quiescent cancer cells, with the risk of de novo cancer development or recurrence. The recent description that adult stem cells primed in vitro may be vehicle for anticancer drug delivery offers a new vision concerning the role of ASCs in breast reconstruction after cancer surgery. Paclitaxel (PTX) is a chemotherapeutic agent acting as a microtu-bule-stabilizing drug inhibiting cancer cell mitotic activity. We optimized PTX loading and release in cultured ASCs and then analyzed the effects of PTX-loaded ASCs and their conditioned medium on CG5 breast cancer survival, proliferation and apoptosis in vitro, and inCG5 xenograft in vivo. We documented that ASCs can uptake and release PTX in vitro, with slight cytotoxic effects. Interestingly, PTX-loaded ASCs in co-culture, as well as conditioned medium alone, inhibited CG5 cell proliferation and survival in vitro and xenograft tumor growth in vivo. The antitumor effect of PTX-loaded ASCs may offer a new perspective concerning the use of ASCs during breast reconstruction becoming an additional local preventive chemotherapeutic agent against tumor recurrence. However, further experiments in vitro and in vivo are needed to collect more evidence confirming the efficacy and safety in cancer patients.

AB - Breast cancer represents the main malignancy in women and autologous fat grafting is a diffuse procedure in the management of post-surgical breast defects causing patients’ psychosocial problems, with high costs for the public health. Recently, beneficial effects of fat grafting during post-surgical breast reconstruction have been amplified from the enrichment with human adipose-derived stem cells (ASCs) present in the stromal vascular fraction (SVF) of adult adipose tissue isolated during intraoperatory procedures. The major concern about the ASC enrichment during post-surgery breast reconstruction depends on their potential ability to release growth factors and hormones that can promote proliferation of residual or quiescent cancer cells, with the risk of de novo cancer development or recurrence. The recent description that adult stem cells primed in vitro may be vehicle for anticancer drug delivery offers a new vision concerning the role of ASCs in breast reconstruction after cancer surgery. Paclitaxel (PTX) is a chemotherapeutic agent acting as a microtu-bule-stabilizing drug inhibiting cancer cell mitotic activity. We optimized PTX loading and release in cultured ASCs and then analyzed the effects of PTX-loaded ASCs and their conditioned medium on CG5 breast cancer survival, proliferation and apoptosis in vitro, and inCG5 xenograft in vivo. We documented that ASCs can uptake and release PTX in vitro, with slight cytotoxic effects. Interestingly, PTX-loaded ASCs in co-culture, as well as conditioned medium alone, inhibited CG5 cell proliferation and survival in vitro and xenograft tumor growth in vivo. The antitumor effect of PTX-loaded ASCs may offer a new perspective concerning the use of ASCs during breast reconstruction becoming an additional local preventive chemotherapeutic agent against tumor recurrence. However, further experiments in vitro and in vivo are needed to collect more evidence confirming the efficacy and safety in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85053255209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053255209&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0203426

DO - 10.1371/journal.pone.0203426

M3 - Article

AN - SCOPUS:85053255209

VL - 13

SP - e0203426

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

ER -